Article info

Download PDFPDF
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial

Authors

  1. Correspondence to Dr Xiaofeng Zeng; zengxfpumc{at}163.com; xiaofeng.zeng{at}cstar.org.cn
View Full Text

Citation

Liu J, Jiang Y, Zhang S, et al
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial

Publication history

  • Received July 8, 2024
  • Accepted November 4, 2024
  • First published November 27, 2024.